ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Public ClinicalTrials.gov record NCT02048059. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Study identification
- NCT ID
- NCT02048059
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Angiochem Inc
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- ANG1005 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2014
- Primary completion
- Feb 29, 2016
- Completion
- Aug 31, 2017
- Last update posted
- Feb 24, 2020
2014 – 2017
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093-0698 | — |
| University of California - LAC Medical Center | Los Angeles | California | 90033 | — |
| University of Southern California - Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UC - Irvine Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| GRU Cancer Center - Georgia Regents University | Augusta | Georgia | 30912 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Maryland - Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| National Cancer Institute | Bethesda | Maryland | 20892-1903 | — |
| Cancer & Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49503 | — |
| University of New Mexico | Albuquerque | New Mexico | 87106 | — |
| The Long Islan Brain Tumor Center at Neurological Surgery P.C. | Commack | New York | 11725 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599-7295 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Magee Womens Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| UPMC Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Univeristy of Texas Health Science Center in San Antonio | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02048059, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2020 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02048059 live on ClinicalTrials.gov.